Does Soluble Fiber Supplementation Result in Lower Postprandial Blood Glucose in Women With Gestational Diabetes Compared With no Supplementation After a Standardized Breakfast?
NCT ID: NCT05925010
Last Updated: 2023-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
67 participants
INTERVENTIONAL
2023-01-02
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Null Hypothesis H0:
Soluble fiber supplementation will not result in a lower postprandial blood glucose increase in women with gestational diabetes compared to no supplementation after consumption of a standardized meal.
Alternative hypothesis H1:
Soluble fiber supplementation will result in a lower postprandial blood glucose increase in women with gestational diabetes compared to no supplementation after consumption of a standardized meal.
Study participants are randomly assigned to the intervention (consumption of a standardized meal and 10g soluble fibre) or control group (consumption of a standardized meal without soluble fibre). After a 2-day wash-out phase, the two groups are switched (the intervention group becomes the control group and vice versa) with the same standardized procedure.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The effect of supplementation of soluble dietary fiber from guar in the form of a dietary food for special medical purposes (Optifibre©) on postprandial glucose levels in women with gestational diabetes after a standardized test meal (Resource cereal porridge©) was consumed with or without supplementation is being investigated.
The aim of this study is to verify whether the use of easily tolerated soluble dietary fiber in addition to nutritional therapy for gestational diabetes can lead to an improvement in glycemic control and thus represent a therapeutic option for diabetic diseases in the future.
Participants:
Women with gestational diabetes meeting the inclusion criteria.
Study drain:
Study participants are recruited via the appointment at the metabolic outpatient clinic of the Mödling district, where diabetes and nutrition training including training on the Contour Next One© blood glucose meter takes place as standard.
If patients meet the inclusion criteria for participation in the study, the nutritional training is followed by an educational interview including signing of the consent form if the patient wishes to participate. After a one-week run-in phase, the participating patients are assigned to the intervention or control group by means of a randomizer. After a 2-day wash-out phase, the two groups are switched (the intervention group becomes the control group and vice versa) with the same standardized procedure.
The procedure is as follows: at the initial appointment in the metabolic outpatient clinic, the participant receives 2 sachets of a standardized cereal porridge, which represents the standardized breakfast, and 1 can of Optifibre©.
In the control phase, the participant consumes the cereal porridge with 200ml of milk after fasting blood glucose is measured. 1 hour after consumption, the postprandial blood glucose value is measured and documented in self-monitoring.
In the intervention phase, participants also replace breakfast with the same porridge, but consume an additional 10g of Optifibre© mixed into the porridge. As in the control phase, fasting blood glucose is measured beforehand and postprandial blood glucose is measured 1 hour after consumption, including documentation.
Intervention and control phase take place consecutively after a wash-out phase of 2 days. During the wash-out phase, the general guidelines for nutrition in gestational diabetes will be followed, no supplementation with Optifibre© will be given.
Participants send the records to [email protected] , the data are then pseudonymized and further processed with the appropriate verification code.
The intervention itself lasts approximately 2 weeks per participant starting with initial training and ending with the transmission of the data.
The total duration of the study is significantly longer, as recruitment is an ongoing process. It is assumed that the total duration of data collection will be at least 6 months, based on the estimate that 3 to 4 patients/week can be included and recruited for the study.
Benefits and risks:
If supplementation of the soluble fiber Guar shows a positive effect on glycemic control of a GDM, consumption of supplements such as Optifibre© represents another option for additional fiber intake and another therapeutic option for diabetic diseases in the future.
There is no disadvantage for the participants in this study. All study participants receive the same nutritional medical training that is also given to non-study participants, and there is no different treatment of the subjects during the course of the study, since each subject undergoes both the intervention and control phases.
Place where the study will be conducted:
This study is conducted by the Landesklinikum Mödling in cooperation with the Medical University of Graz.
Duration and schedule:
The concept submission took place in May 2022 and the study will be completed in July 2023.
Funding of the study:
As this is a final thesis of the university course "Applied Nutritional Medicine" at the Medical University of Graz to obtain the Master of Science of applied nutritional medicine, there is no funding involved.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supplementation with soluble fibre from guar
In the intervention group, the patients consume the standardized meal instead of breakfast and add 10 g of soluble fiber in the form of Optifibre (food for special medical purposes) to this cereal porridge.
Supplementation with soluble fibre from guar (Optifibre©)
10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
No supplementation with soluble fibre from guar
In the control group, the patients eat the standardized meal without adding soluble fiber in the form of Optifibre.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supplementation with soluble fibre from guar (Optifibre©)
10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Second (13th to 28th week of pregnancy) and/or third trimester (29th to 40th week of pregnancy).
* Sufficient knowledge of German to perform self-monitoring correctly
* No intolerance to standardised meals (cereal porridge) or BST supplements
* No concomitant disease requiring special dietary management
Exclusion Criteria
* First trimester of pregnancy
* Intolerance/contraindications to any of the ingredients of Resource cereal© or Optifibre©.
* Insufficient language skills to perform self-monitoring
* Insufficient language skills to adequately implement study procedure/intervention
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mödling Hospital
OTHER
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landesklinikum Mödling
Mödling, Lower Austria, Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nawras Al-Taie, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS1-EK-4/809-2022
Identifier Type: -
Identifier Source: org_study_id